Global venture capital firm New Venture Partners, which specializes in corporate spinouts, has named Paul Horn, former director of IBM Research, to its advisory board.
Horn led the information technology efforts of IBM Research for more than a decade. During his tenure there, Horn oversaw the company's cross-disciplinary development of the Blue Gene supercomputer.
GenoLogics, a developer of lab and data management life science software, has tapped Sal Sanci to be its vice president of products, and Paul Ford to be vice president of finance.
Sanci has over 20 years of technology experience, and most recently was the technology vice president at Teligence.
Paul Ford joins GenoLogics from private equity firm PineRidge Partners in Tokyo, where he most recently held the position of executive director.
James DeGreef, the founder, now takes on a new role as vice president of market strategy, and Don Listwin, formerly of Cisco Systems, has been brought in to join as chairman of the company’s board of directors.
Empire Genomics, which develops high throughput technologies to enable genome-wide analyses, has formed its scientific advisory board.
Members of the new SAB are culled from a combination of scientific and medical backgrounds including and clinical and operational experience in molecular genetics .
The board will support the company as it develops diagnostic and research technologies for cancer biology, biomarkers, drug discovery, prenatal screening, developmental disorders, autism and other genomic related areas, the company said.
These members include: Stuart Schwartz, director of genetic diagnostic services, and professor of human genetics, medicine, and pathology, as well as the director of the clinical cytogenetics laboratory at the University of Chicago; Marilyn Slovak, director of cytogenetics and professor of pathology at the City of Hope National Medical Center in Duarte, Calif.; Michael Liebman, executive director of the Windber Research Institute; and Laura Reid, senior director, marketing and external scientific affairs at Expression Analysis.
Simulations Plus, a provider of software for pharmaceutical discovery and development, appointed Wayne Rosenberger to its board of directors at its Nov. 30 meeting.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said in a statement that Rosenberg’s four decades of banking and finance experience is augmented by chairmanship and director positions for many organizations, including the Antelope Valley Hospital Finance Committee.